Latest News

Parabilis Medicines, a biopharmaceutical company, files for US IPO

According to a regulatory filing, Parabilis Medicines filed on Tuesday for an initial public offering in the United States. The company said it would use a portion of the proceeds from the IPO to help develop its drug pipeline.

Investors' appetite for new listings is increasing after companies like?AI chipmaker Cerebras Systems, and geothermal power firm Fervo Energy have made strong debuts on the market.

Parabilis, a biopharmaceutical firm in clinical development, is developing Helicons. This class of therapies targets proteins that are difficult to treat.

The filing stated that the company's "lead drug" candidate, zolucatetide has been evaluated by?more 150 patients?and has demonstrated encouraging clinical results across several solid tumour types.

Parabilis intends to use the IPO funds, as well as funds from a private placement, to advance clinical research on zolucatetide and expand its broader pipeline, support its Helicon platform, and for general corporate purposes.

Regeneron Pharmaceuticals announced on Monday that it has partnered up with Parabilis. Parabilis could receive a milestone payment of up to $2.2 billion for developing treatments against hard-to reach disease targets.

According to the filing, as part of their research collaboration, 'Regeneron' has agreed to purchase about $75 million?of Parabilis shares in the simultaneous private placement tied to IPO.

Parabilis is slated to list on Nasdaq under the symbol "PBLS".

Underwriters include Leerink Partners and BofA Securities. Reporting and editing by Shashesh Kuber in Bengaluru.

(source: Reuters)